Okami Medical, a private medtech company focused on embolization solutions, spent the week highlighting its LOBO vascular occlusion system and proprietary HDBRAID technology. The company used LinkedIn and recent conference activity to reinforce LOBO’s positioning as an advanced option for peripheral vascular embolization.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Marketing materials described the LOBO system as occlusive, deliverable and stable, with an “embolization trifecta” value proposition centered on reliability and ease of use. Okami directed clinicians to product videos and its website, signaling an emphasis on physician education and awareness-building.
Recent communications also referenced expanding real-world use, including a case where the LOBO-9 device was used to treat an 86-year-old patient with splenic trauma, achieving rapid vessel occlusion through a guide catheter without additional embolic devices. This example supports claims around procedural speed, efficiency and the potential to reduce device count in high-acuity settings.
Around the GEST 2026 endovascular conference in New York, Okami showcased LOBO HDBRAID at its booth and supported hands-on workshops and masterclasses focused on coils, plugs and stent grafts. This education-centric strategy aims to deepen engagement with interventional radiologists and could translate into higher procedure volumes over time.
Collectively, the week’s updates point to steady commercialization efforts and growing clinical validation for the LOBO platform, even though detailed regulatory, sales and reimbursement metrics remain undisclosed. Overall, it was a constructive week for Okami Medical, marked by increased product visibility and continued momentum in the embolization market.